Search

Your search keyword '"Solomon, Scott"' showing total 6,828 results
Start Over Author "Solomon, Scott"
6,828 results on '"Solomon, Scott"'

2. Future humans : inside the science of our continuing evolution.

Author

Solomon, Scott

Subjects
Behavior evolution, Evolution (Biology), Human evolution -- Forecasting, Human evolution, Biological Evolution, Hominidae
Abstract

Summary: "Evolutionary biologist Scott Solomon draws on the explosion of discoveries in recent years to examine the future evolution of our species. Combining knowledge of our past with current trends, Solomon offers convincing evidence that evolutionary forces still affect us today. But how will modernization--including longer lifespans, changing diets, global travel, and widespread use of medicine and contraceptives--affect our evolutionary future?" --publisher description.

Published
2016

3. Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.

Author

Solomon, Scott, Lowenstein, Charles, Bhatt, Ankeet, Peikert, Alexander, Vardeny, Orly, Kosiborod, Mikhail, Berger, Jeffrey, Reynolds, Harmony, Mavromichalis, Stephanie, Barytol, Anya, Althouse, Andrew, Luther, James, Leifer, Eric, Kindzelski, Andrei, Cushman, Mary, Gong, Michelle, Khatri, Pooja, Kim, Keri, Baumann Kreuziger, Lisa, Wahid, Lana, Kirwan, Bridget-Anne, Geraci, Mark, Neal, Matthew, Hochman, Judith, and Kornblith, Lucy

Subjects
COVID-19, P-selectin, crizanlizumab, Humans, COVID-19, SARS-CoV-2, P-Selectin, Endothelial Cells, Treatment Outcome
Abstract

BACKGROUND: COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19. METHODS: An international, adaptive, randomized controlled platform trial, funded by the National Heart, Lung, and Blood Institute, randomly assigned 422 patients hospitalized with COVID-19 with moderate or severe illness to receive either a single infusion of the P-selectin inhibitor crizanlizumab (at a dose of 5 mg/kg) plus standard of care or standard of care alone in an open-label 1:1 ratio. The primary outcome was organ support-free days, evaluated on an ordinal scale consisting of the number of days alive free of organ support through the first 21 days after trial entry. RESULTS: The study was stopped for futility by the data safety monitoring committee. Among 421 randomized patients with known 21-day outcomes, 163 patients (77%) randomized to the crizanlizumab plus standard-of-care arm did not require any respiratory or cardiovascular organ support compared with 169 (80%) in the standard-of-care-alone arm. The adjusted odds ratio for the effect of crizanlizumab on organ support-free days was 0.70 (95% CI, 0.43-1.16), where an odds ratio >1 indicates treatment benefit, yielding a posterior probability of futility (odds ratio 1] = 0.879). CONCLUSIONS: Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ support-free days in patients hospitalized with COVID-19. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04505774.

Published
2023

4. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF

Author

Dewan, Pooja, Shen, Li, Pedro Ferreira, João, Jhund, Pardeep S., Anand, Inder S., Chandra, Alvin, Chiang, Lu-May, Claggett, Brian, Desai, Akshay S., Gong, Jianjian, Lam, Carolyn S.P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Solomon, Scott D., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

5. Machine Learning to Understand Genetic and Clinical Factors Associated With the Pulse Waveform Dicrotic Notch.

Author

Cunningham, Jonathan, Di Achille, Paolo, Morrill, Valerie, Weng, Lu-Chen, Choi, Seung, Khurshid, Shaan, Nauffal, Victor, Solomon, Scott, Batra, Puneet, Ho, Jennifer, Philippakis, Anthony, Ellinor, Patrick, Lubitz, Steven, and Pirruccello, James

Subjects
Humans, Cardiovascular Diseases, Genome-Wide Association Study, Coronary Artery Disease, Risk Factors, Phenotype
Abstract

BACKGROUND: Absence of a dicrotic notch on finger photoplethysmography is an easily ascertainable and inexpensive trait that has been associated with age and prevalent cardiovascular disease. However, the trait exists along a continuum, and little is known about its genetic underpinnings or prognostic value for incident cardiovascular disease. METHODS: In 169 787 participants in the UK Biobank, we identified absent dicrotic notch on photoplethysmography and created a novel continuous trait reflecting notch smoothness using machine learning. Next, we determined the heritability, genetic basis, polygenic risk, and clinical relations for the binary absent notch trait and the newly derived continuous notch smoothness trait. RESULTS: Heritability of the continuous notch smoothness trait was 7.5%, compared with 5.6% for the binary absent notch trait. A genome-wide association study of notch smoothness identified 15 significant loci, implicating genes including NT5C2 (P=1.2×10-26), IGFBP3 (P=4.8×10-18), and PHACTR1 (P=1.4×10-13), compared with 6 loci for the binary absent notch trait. Notch smoothness stratified risk of incident myocardial infarction or coronary artery disease, stroke, heart failure, and aortic stenosis. A polygenic risk score for notch smoothness was associated with incident cardiovascular disease and all-cause death in UK Biobank participants without available photoplethysmography data. CONCLUSIONS: We found that a machine learning derived continuous trait reflecting dicrotic notch smoothness on photoplethysmography was heritable and associated with genes involved in vascular stiffness. Greater notch smoothness was associated with greater risk of incident cardiovascular disease. Raw digital phenotyping may identify individuals at risk for disease via specific genetic pathways.

Published
2023

6. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.

Author

Metra, Marco, Pagnesi, Matteo, Claggett, Brian, Díaz, Rafael, Felker, G, McMurray, John, Solomon, Scott, Bonderman, Diana, Fang, James, Fonseca, Cândida, Goncalvesova, Eva, Howlett, Jonathan, Li, Jing, OMeara, Eileen, Miao, Zi, Abbasi, Siddique, Heitner, Stephen, Kupfer, Stuart, Malik, Fady, and Teerlink, John

Subjects
Cardiovascular outcomes trial, Heart failure, Inotrope, Myotrope, Omecamtiv mecarbil, Humans, Blood Pressure, Stroke Volume, Heart Failure, Ventricular Dysfunction, Left
Abstract

AIM: Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients. This study examined its efficacy and tolerability in patients with SBP ≤100 mmHg enrolled in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF). METHODS AND RESULTS: The GALACTIC-HF enrolled patients with baseline SBP ≥85 mmHg with a primary outcome of time to cardiovascular death or first heart failure event. In this analysis, patients were divided according to their baseline SBP (≤100 vs. >100 mmHg). Among the 8232 analysed patients, 1473 (17.9%) had baseline SBP ≤100 mmHg and 6759 (82.1%) had SBP >100 mmHg. The primary outcome occurred in 715 (48.5%) and 2415 (35.7%) patients with SBP ≤100 and >100 mmHg, respectively. Patients with lower SBP were at higher risk of adverse outcomes. Omecamtiv mecarbil, compared with placebo, appeared to be more effective in reducing the primary composite endpoint in patients with SBP ≤100 mmHg [hazard ratio (HR), 0.81; 95% confidence interval (CI), 0.70-0.94] compared with those with SBP >100 mmHg (HR, 0.95; 95% CI, 0.88-1.03; P-value for interaction = 0.051). In both groups, omecamtiv mecarbil did not change SBP values over time and did not increase the risk of adverse events, when compared with placebo. CONCLUSION: In GALACTIC-HF, risk reduction of heart failure outcomes with omecamtiv mecarbil compared with placebo was large and significant in patients with low SBP. Omecamtiv mecarbil did not affect SBP and was well tolerated independent of SBP values.

Published
2022

8. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Author

Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Birkenfeld, Andreas L., Ceriello, Antonio, Cheng, Alice, Davies, Melanie, Edelman, Steve, Forst, Thomas, Giorgino, Francesco, Green, Jennifer, Groop, Per-Henrik, Hadjadj, Samy, J.L.Heerspink, Hiddo, Hompesch, Marcus, Izthak, Baruch, Ji, Linong, Kanumilli, Naresh, Mankovsky, Boris, Mathieu, Chantal, Miszon, Martin, Mustafa, Reem, Nauck, Michael, Pecoits-Filho, Roberto, Pettus, Jeremy, Ranta, Kari, Rodbard, Helena W., Rossing, Peter, Ryden, Lars, Schumm-Draeger, Petra-Maria, Solomon, Scott D., Škrha, Jan, Topsever, Pinar, Vilsbøll, Tina, Wilding, John, and Standl, Eberhard

Published
2023
Full Text
View/download PDF

9. Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations.

Author

Jering, Karola, Campagnari, Claudio, Claggett, Brian, Adler, Eric, Ahmad, Faraz, Voors, Adriaan, Solomon, Scott, Greenberg, Barry, Klein, Liviu, and Yagil, Avi

Subjects
Clinical trial efficiency, Heart failure, Machine learning, Prognostic enrichment, Risk scores, Trial enrolment strategies, Clinical Trials as Topic, Heart Failure, Humans, Machine Learning, Prognosis, Risk Factors, Stroke Volume, Ventricular Function, Left
Abstract

AIMS: Prognostic enrichment strategies can make trials more efficient, although potentially at the cost of diminishing external validity. Whether using a risk score to identify a population at increased mortality risk could improve trial efficiency is uncertain. We aimed to assess whether Machine learning Assessment of RisK and EaRly mortality in Heart Failure (MARKER-HF), a previously validated risk score, could improve clinical trial efficiency. METHODS AND RESULTS: Mortality rates and association of MARKER-HF with all-cause death by 1 year were evaluated in four community-based heart failure (HF) and five HF clinical trial cohorts. Sample size required to assess effects of an investigational therapy on mortality was calculated assuming varying underlying MARKER-HF risk and proposed treatment effect profiles. Patients from community-based HF cohorts (n = 11 297) had higher observed mortality and MARKER-HF scores than did clinical trial patients (n = 13 165) with HF with either reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). MARKER-HF score was strongly associated with risk of 1-year mortality both in the community (hazard ratio [HR] 1.48, 95% confidence interval [CI] 1.44-1.52) and clinical trial cohorts with HFrEF (HR 1.41, 95% CI 1.30-1.54), and HFpEF (HR 1.74, 95% CI 1.53-1.98), per 0.1 increase in MARKER-HF. Using MARKER-HF to identify patients for a hypothetical clinical trial assessing mortality reduction with an intervention, enabled a reduction in sample size required to show benefit. CONCLUSION: Using a reliable predictor of mortality such as MARKER-HF to enrich clinical trial populations provides a potential strategy to improve efficiency by requiring a smaller sample size to demonstrate a clinical benefit.

Published
2022

12. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

Author

Gustafsson, Finn, Petrie, Mark C., Komtebedde, Jan, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G.F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Solomon, Scott D., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

13. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Author

Apperloo, Ellen M, Neuen, Brendon L, Fletcher, Robert A, Jongs, Niels, Anker, Stefan D, Bhatt, Deepak L, Butler, Javed, Cherney, David Z I, Herrington, William G, Inzucchi, Silvio E, Jardine, Meg J, Liu, Chih-Chin, Mahaffey, Kenneth W, McGuire, Darren K, McMurray, John J V, Neal, Bruce, Packer, Milton, Perkovic, Vlado, Sabatine, Marc S, Solomon, Scott D, Staplin, Natalie, Szarek, Michael, Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C, Wiviott, Stephen D, Zannad, Faiez, and Heerspink, Hiddo J L

Published
2024
Full Text
View/download PDF

14. Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy

Author

Kittipibul, Veraprapas, Vaduganathan, Muthiah, Ikeaba, Uchechukwu, Chiswell, Karen, Butler, Javed, DeVore, Adam D., Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., Linganathan, Karthik K., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C., and Greene, Stephen J.

Published
2024
Full Text
View/download PDF

18. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials

Author

Skaarup, Kristoffer Grundtvig, Lassen, Mats Christian Højbjerg, Modin, Daniel, Johansen, Niklas Dyrby, Loiacono, Matthew M., Harris, Rebecca C., Lee, Jason K.H., Dufournet, Marine, Vardeny, Orly, Peikert, Alexander, Claggett, Brian, Solomon, Scott D., Jensen, Jens Ulrik Stæhr, and Biering-Sørensen, Tor

Published
2024
Full Text
View/download PDF

24. Rationale and design of NUDGE-FLU-CHRONIC and NUDGE-FLU-2: Two nationwide randomized trials of electronic nudges to increase influenza vaccination among patients with chronic diseases and older adults during the 2023/2024 influenza season

Author

Johansen, Niklas Dyrby, Vaduganathan, Muthiah, Bhatt, Ankeet S., Modin, Daniel, Chatur, Safia, Claggett, Brian L., Janstrup, Kira Hyldekær, Larsen, Carsten Schade, Larsen, Lykke, Wiese, Lothar, Dalager-Pedersen, Michael, Køber, Lars, Solomon, Scott D., Sivapalan, Pradeesh, Jensen, Jens Ulrik Stæhr, Martel, Cyril Jean-Marie, Krause, Tyra Grove, and Biering-Sørensen, Tor

Published
2024
Full Text
View/download PDF

25. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study

Author

Felker, G. Michael, Solomon, Scott D., Metra, Marco, Mcmurray, John J.V., Diaz, Rafael, Claggett, Brian, Lanfear, David E., Vandekerckhove, Hans, Biering-Sørensen, Tor, Lopes, Renato D., Arias-Mendoza, Alexandra, Momomura, Shin-Ichi, Corbalan, Ramon, Ramires, Felix J.A., Zannad, Faiez, Heitner, Stephen B., Divanji, Punag H., Kupfer, Stuart, Malik, Fady I., and Teerlink, John R.

Published
2024
Full Text
View/download PDF

26. Daprodustat and Heart Failure in CKD

Author

Cunningham, Jonathan W., Claggett, Brian L., Lopes, Renato D., McMurray, John J.V., Perkovic, Vlado, Carroll, Kevin, Hiemstra, Thomas, Khavandi, Kaivan, Lukas, Mary Ann, Ranganathan, Prerna, Shannon, Jennifer, van Adelsberg, Janet, Singh, Ajay K., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

27. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER

Author

Butt, Jawad H., Jhund, Pardeep S., Docherty, Kieran F., Claggett, Brian L., Vaduganathan, Muthiah, Bachus, Erasmus, Hernandez, Adrian F., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Kosiborod, Mikhail N., Desai, Akshay S., Køber, Lars, Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

29. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

Author

Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

32. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis

Author

Ioannou, Adam, Cappelli, Francesco, Emdin, Michele, Nitsche, Christian, Longhi, Simone, Masri, Ahmad, Cipriani, Alberto, Zampieri, Mattia, Colio, Federica, Poledniczek, Michael, Porcari, Aldostefano, Razvi, Yousuf, Aimo, Alberto, Vergaro, Giuseppe, De Michieli, Laura, Rauf, Muhammad U., Patel, Rishi K., Villanueva, Eugenia, Lustig, Yael, Venneri, Lucia, Martinez-Naharro, Ana, Lachmann, Helen, Wechalekar, Ashutosh, Whelan, Carol, Petrie, Aviva, Hawkins, Philip N., Solomon, Scott, Gillmore, Julian D., and Fontana, Marianna

Published
2024
Full Text
View/download PDF

33. Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial

Author

Dehghani, Payam, Srivatsav, Varun, Vardeny, Orly, Grewal, Jasmine, Opotowsky, Alexander R., Muhll, Isabelle Vonder, Keir, Michelle, Ducas, Robin, Singh, Jyotpal, Kim, KyungMann, Joseph, Jacob, Aboulhosn, Jamil, Havighurst, Tom, Hegde, Sheila M., Bhatt, Deepak L., Solomon, Scott, Farkouh, Michael, Goodman, Shaun G., Moe, Tabitha G., and Udell, Jacob A.

Published
2024
Full Text
View/download PDF

35. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

Author

Peikert, Alexander, Bart, Bradley A., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Kosiborod, Mikhail N., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Hernandez, Adrian F., Shah, Sanjiv J., Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D., and Vardeny, Orly

Published
2024
Full Text
View/download PDF

39. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER

Author

BUTT, JAWAD H., JERING, KAROLA, DE BOER, RUDOLF A., CLAGGETT, BRIAN L., DESAI, AKSHAY S., HERNANDEZ, ADRIAN F., INZUCCHI, SILVIO E., JHUND, PARDEEP S., KØBER, LARS, KOSIBOROD, MIKHAIL N., LAM, CAROLYN S.P., MARTINEZ, FELIPE A., PONIKOWSKI, PIOTR, SABATINE, MARC S., SHAH, SANJIV J., VADUGANATHAN, MUTHIAH, LANGKILDE, ANNA MARIA, BENGTSSON, OLOF, PETERSSON, MAGNUS, SJÖSTRAND, MIKAELA, WILDERÄNG, ULRICA, SOLOMON, SCOTT D., and MCMURRAY, JOHN J.V.

Published
2024
Full Text
View/download PDF

40. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week

Author

Fiuzat, Mona, Hamo, Carine E, Butler, Javed, Abraham, William T, DeFilippis, Ersilia M, Fonarow, Gregg C, Lindenfeld, Joann, Mentz, Robert J, Psotka, Mitchell A, Solomon, Scott D, Teerlink, John R, Vaduganathan, Muthiah, Vardeny, Orly, McMurray, John JV, and O’Connor, Christopher M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Heart Disease, Cardiovascular, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Cardiovascular Agents, Clinical Trials as Topic, Heart Failure, Humans, Periodicals as Topic, Stroke Volume, clinical trials, device therapy, drug therapy, FDA, guideline directed, medical therapy, heart failure, HFrEF, medication, guideline directed medical therapy, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.

Published
2022

41. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Author

Kantarjian, Hagop M, Begna, Kebede H, Altman, Jessica K, Goldberg, Stuart L, Sekeres, Mikkael A, Strickland, Stephen A, Arellano, Martha L, Claxton, David F, Baer, Maria R, Gautier, Marc, Berman, Ellin, Seiter, Karen, Solomon, Scott R, Schiller, Gary J, Luger, Selina M, Butrym, Aleksandra, Gaidano, Gianluca, Thomas, Xavier G, Montesinos, Pau, Rizzieri, David A, Quick, Donald P, Venugopal, Parameswaran, Gaur, Rakesh, Maness, Lori J, Kadia, Tapan M, Ravandi, Farhad, Buyse, Marc E, and Chiao, Judy H

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Arabinonucleosides, Azacitidine, Cytosine, Decitabine, Humans, Leukemia, Myeloid, Acute, Treatment Outcome, acute myeloid leukemia, decitabine, hypomethylation, sapacitabine, therapy, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low-intensity therapy, to elderly patients with newly diagnosed AML.MethodsThis randomized, open-label, phase 3 study (SEAMLESS) was conducted at 87 sites in 11 countries. Patients aged ≥70 years who were not candidates for or chose not to receive standard induction chemotherapy were randomized 1:1 to arm A (decitabine in alternating cycles with sapacitabine) received 1-hour intravenous infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 8 weeks (first cycle and subsequent odd cycles) and sapacitabine 300 mg twice daily on 3 consecutive days per week for 2 weeks every 8 weeks (second cycle and subsequent even cycles) or to control arm C who received 1-hour infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 4 weeks. Prior hypomethylating agent therapy for preexisting myelodysplastic syndromes or myeloproliferative neoplasms was an exclusion criterion. Randomization was stratified by antecedent myelodysplastic syndromes or myeloproliferative neoplasms, white blood cell count (

Published
2021

43. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial

Author

Wang, Xiaowen, Lam, Carolyn S.P., Vaduganathan, Muthiah, Kondo, Toru, Yang, Mingming, Han, Yaling, Pham, Vinh Nguyen, Chiang, Chern-En, Kitakaze, Masafumi, Miao, Zi Michael, Jhund, Pardeep S., Desai, Akshay S., Inzucchi, Silvio E., de Boer, Rudolf A., Martinez, Felipe A., Kosiborod, Mikhail N., Hernandez, Adrian F., Claggett, Brian, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

44. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry

Author

BHATT, ANKEET S., FONAROW, GREGG C., GREENE, STEPHEN J., HOLMES, DAJUANICIA N., ALHANTI, BROOKE, DEVORE, ADAM D., BUTLER, JAVED, HEIDENREICH, PAUL A., HUANG, JOANNA C., KITTLESON, MICHELLE M., LINGANATHAN, KARTHIK, JOYNTMADDOX, KAREN E., MCDERMOTT, JAMES J., OWENS, ANJALI TIKU, PETERSON, PAMELA N., SOLOMON, SCOTT D., VARDENY, ORLY, YANCY, CLYDE W., and VADUGANATHAN, MUTHIAH

Published
2024
Full Text
View/download PDF

46. Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis

Author

Farhadfar, Nosha, Rashid, Nahid, Chen, Karen, DeVos, Jakob, Wang, Tao, Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Hamilton, Betty K., Hematti, Peiman, Gadalla, Shahinaz M., Solomon, Scott R., El Jurdi, Najla, Lee, Catherine J., MacMillan, Margaret L., Rangarajan, Hemalatha G., Schoemans, Hélène, Sharma, Akshay, Spellman, Stephen R., Wingard, John R., and Lee, Stephanie J.

Published
2024
Full Text
View/download PDF

48. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Author

MASRI, AHMAD, SHERRID, MARK V., ABRAHAM, THEODORE P., CHOUDHURY, LUBNA, GARCIA-PAVIA, PABLO, KRAMER, CHRISTOPHER M., BARRIALES-VILLA, ROBERTO, OWENS, ANJALI T., RADER, FLORIAN, NAGUEH, SHERIF F., OLIVOTTO, IACOPO, SABERI, SARA, TOWER-RADER, ALBREE, WONG, TIMOTHY C., COATS, CAROLINE J., WATKINS, HUGH, FIFER, MICHAEL A., SOLOMON, SCOTT D., HEITNER, STEPHEN B., JACOBY, DANIEL L., KUPFER, STUART, MALIK, FADY I., MENG, LISA, SOHN, REGINA L., WOHLTMAN, AMY, and MARON, MARTIN S.

Published
2024
Full Text
View/download PDF

49. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial

Author

Johansen, Niklas Dyrby, Modin, Daniel, Skaarup, Kristoffer Grundtvig, Nealon, Joshua, Samson, Sandrine, Dufournet, Marine, Loiacono, Matthew M., Harris, Rebecca C., Larsen, Carsten Schade, Jensen, Anne Marie Reimer, Landler, Nino Emanuel, Claggett, Brian L., Solomon, Scott D., Landray, Martin J., Gislason, Gunnar H., Køber, Lars, Jensen, Jens Ulrik Stæhr, Sivapalan, Pradeesh, Vestergaard, Lasse Skafte, Valentiner-Branth, Palle, Krause, Tyra Grove, and Biering-Sørensen, Tor

Published
2024
Full Text
View/download PDF

50. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper

Author

Lala, Anuradha, Hamo, Carine E., Bozkurt, Biykem, Fiuzat, Mona, Blumer, Vanessa, Bukhoff, Daniel, Butler, Javed, Costanzo, Maria Rosa, Felker, G. Michael, Filippatos, Gerasimos, Konstam, Marvin A., McMurray, John J.V., Mentz, Robert J., Metra, Marco, Psotka, Mitchell A., Solomon, Scott D., Teerlink, John, Abraham, William T., and O’Connor, Christopher M.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results